Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Galli

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|August 28, 2014
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyPaola Tacchetti, Carolina Terragna, Monica Galli, et al.
Blood|August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label studyAlessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Lancet (London, England)|December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyMichele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Bone Marrow Transplantation|November 27, 2019
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myelomaGiulia Tolomelli, Katia Mancuso, Paola Tacchetti, et al.
Lancet (London, England)|March 15, 2006
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialAntonio Palumbo, Sara Bringhen, Tommaso Caravita, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Haematologica|October 6, 2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysisSilvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|August 28, 2014
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyPaola Tacchetti, Carolina Terragna, Monica Galli, et al.
Blood|August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label studyAlessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Lancet (London, England)|December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyMichele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Bone Marrow Transplantation|November 27, 2019
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myelomaGiulia Tolomelli, Katia Mancuso, Paola Tacchetti, et al.
Lancet (London, England)|March 15, 2006
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialAntonio Palumbo, Sara Bringhen, Tommaso Caravita, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Haematologica|October 6, 2022
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysisSilvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Pageof 6